Acquisition Due-Diligence, Rare Diseases Case Study

European growth via acquisition, due-diligence of target company vis-à-vis reimbursement planning, staffing, compliance and risks to deal-valuation model

Background

• Client sought acquisition of a rare-disease company with European infrastructure to expand geographic footprint
• Project request was to analyze key products included in acquisition for risks to deal valuation, areas for further investment, and launch optimization needs
• Constructively engage with other consultants that client engaged

LatticePoint Engagement

• Assess pricing strategy, risks in local access negotiations, quality of value story, etc.
• Interview target-company senior leaders for strategic insights, negotiation and launch planning
• Estimate in-country and above-country headcount needs to optimize launch vs. existing headcount

Acquisition approved by C-suite and board; deal terms adjusted to include adoption of “quiet period” for pricing negotiations to ensure no sub-optimal prices agreed prior to deal-closure.